Connect Biopharma Holdings Ltd. has announced the expansion of its Board of Directors from six to seven members, appointing industry veteran Jim Schoeneck as a new director. Schoeneck brings over 40 years of experience in developing and commercializing medicines, and he currently serves as Chairman of the Board of Directors for FibroGen, Inc. and Calidi Biotherapeutics, Inc. His appointment is expected to aid in advancing the development and commercialization of rademikibart, a treatment for asthma and COPD.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9498042-en) on July 22, 2025, and is solely responsible for the information contained therein.